Moderate to Severe Active Ulcerative Colitis research hub

A Parallel-Group Treatment, Double-Blind, 2-Arm Study to Investigate the Comparative Efficacy, Safety, and Immunogenicity Between Intravenous AVT16 and Entyvio® in Male and Female Subjects Aged 18 to 80 Years Inclusive with Moderate to Severe Active Ulcerative Colitis

This study is comparing two medicines, AVT16 and Entyvio, for people aged 18-80 with moderate to severe ulcerative colitis. It will check how well they work, how safe they are, and how the body reacts to them over 52 weeks. The main goal is to see if symptoms improve after 6 weeks.